Neurocrine Biosciences (NASDAQ:NBIX) Posts Earnings Results, Misses Expectations By $0.48 EPS

Neurocrine Biosciences (NASDAQ:NBIX) issued its quarterly earnings results on Wednesday. The company reported $1.88 EPS for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48), FiscalAI reports. The business had revenue of $805.50 million for the quarter, compared to analyst estimates of $804.21 million. Neurocrine Biosciences had a return on equity of 17.24% and a net margin of 16.73%.Neurocrine Biosciences’s revenue for the quarter was up 28.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.69 EPS.

Here are the key takeaways from Neurocrine Biosciences’ conference call:

• INGREZZA posted a record year with double‑digit volume growth and management guided 2026 sales of $2.7–$2.8 billion, driven by expanded access and a larger salesforce.
• CRENESSITY exceeded expectations in its first full year with over $300 million in net sales and prescriptions covering roughly 10% of the classic CAH population, supporting the company’s view it can become a second blockbuster.
• The pipeline is progressing rapidly — two Phase 3 neuropsychiatry programs (osavampator in MDD and direlotide in schizophrenia) target top‑line data in 2027 and NBI‑890 has entered Phase 2 for tardive dyskinesia, setting up a data‑rich 2027.
• Financials are strong with total product sales above $2.8 billion (22% YoY), cash increasing to $2.5 billion, and roughly 30% non‑GAAP operating margin, enabling continued SG&A and R&D investments.
• Management acknowledged pricing concessions and formulary access investments reduced net pricing in 2025 and noted potential contracting/competitive pressure (deutetrabenazine MFP negotiations in 2027) that could weigh on future pricing and margins.

Neurocrine Biosciences Stock Up 0.9%

Shares of NBIX stock traded up $1.05 during trading hours on Friday, hitting $124.15. 761,295 shares of the company’s stock traded hands, compared to its average volume of 1,203,498. The stock’s fifty day simple moving average is $140.77 and its two-hundred day simple moving average is $140.46. Neurocrine Biosciences has a 12-month low of $84.23 and a 12-month high of $160.18. The stock has a market cap of $12.38 billion, a price-to-earnings ratio of 26.69, a PEG ratio of 0.64 and a beta of 0.31.

Insider Activity

In related news, Director George J. Morrow sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $143.37, for a total transaction of $2,150,550.00. Following the completion of the sale, the director owned 7,068 shares of the company’s stock, valued at $1,013,339.16. This trade represents a 67.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Leslie V. Norwalk sold 1,190 shares of the company’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $155.09, for a total value of $184,557.10. Following the transaction, the director directly owned 6,239 shares in the company, valued at approximately $967,606.51. The trade was a 16.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 61,966 shares of company stock valued at $8,625,166 in the last quarter. 4.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of large investors have recently made changes to their positions in the company. Geneos Wealth Management Inc. boosted its holdings in shares of Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after buying an additional 135 shares during the last quarter. Meeder Asset Management Inc. raised its position in Neurocrine Biosciences by 651.6% in the fourth quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock worth $33,000 after acquiring an additional 202 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in shares of Neurocrine Biosciences during the 4th quarter worth $39,000. Employees Retirement System of Texas bought a new stake in shares of Neurocrine Biosciences during the 3rd quarter valued at $149,000. Finally, Vise Technologies Inc. bought a new position in Neurocrine Biosciences in the 4th quarter worth $200,000. 92.59% of the stock is currently owned by institutional investors.

Trending Headlines about Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Citigroup raised its price target to $204 and maintained a Buy rating, signaling continued analyst conviction in Neurocrine’s longer‑term upside. Citigroup raises PT to $204
• Positive Sentiment: Analysts and notes from firms like Bank of America, Needham and TD Cowen reiterated Buy/Outperform views, highlighting a durable Ingrezza franchise and pipeline upside (Crenessity uptake) that support longer‑term growth expectations. Durable Ingrezza franchise and Crenessity uptake support Buy
• Positive Sentiment: Q4/2025 revenue and product sales showed strong year‑over‑year growth (total net product sales $798.3M; full‑year product sales $2.83B) and the company finished the year with stronger cash metrics, which supports financial flexibility. Q4 and full-year 2025 financial results
• Neutral Sentiment: Company Q4 earnings call transcripts and slide deck are available for investors digging into guidance details and management commentary. Q4 2025 earnings call transcript
• Neutral Sentiment: Several analyst roundups and forecasts (consensus price target median near $179) summarize divergent Street views — plenty of buy ratings but a range of PTs reflecting model differences. Analyst projections roundup
• Negative Sentiment: EPS missed consensus — company reported $1.88 EPS vs. higher Street estimates (and some outlets noted larger misses vs certain consensus figures), which pressured stock sentiment after the print. Earnings report and EPS miss
• Negative Sentiment: Management offered cautious 2026 Ingrezza guidance (range disclosed) and commentary that some investors read as near‑term conservatism — several outlets flagged the guidance as a reason for the post‑earnings pullback. Shares tumble on disappointing Ingrezza guidance
• Negative Sentiment: Multiple shops trimmed price targets (Wells Fargo to $175, RBC to $177, BMO to $140) even while many maintained Buy/Outperform ratings — the cuts reflect near‑term margin/guidance risk and drive headline volatility. Analyst PT actions

Wall Street Analyst Weigh In

NBIX has been the topic of a number of research reports. Piper Sandler upped their price target on Neurocrine Biosciences from $175.00 to $179.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. Morgan Stanley restated an “equal weight” rating and set a $175.00 price target (up from $173.00) on shares of Neurocrine Biosciences in a research note on Thursday, January 8th. JPMorgan Chase & Co. reduced their target price on Neurocrine Biosciences from $179.00 to $177.00 and set an “overweight” rating for the company in a research report on Monday, January 12th. Stifel Nicolaus lifted their price target on shares of Neurocrine Biosciences from $183.00 to $188.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Neurocrine Biosciences in a report on Thursday, January 22nd. Sixteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $177.42.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.